There are thousands of diseases without effective therapies of any kind. Accelerated approval represents the quickest way to get promising treatments to people desperate for them.
Imagine being told there’s a drug that might save your life — but your insurance won’t cover it for 18 months.
That’s the reality for patients under a new policy from Independence Blue Cross, a Philadelphia-based insurer. The insurer announced earlier this year that it will delay coverage of therapies that have received “accelerated approval” from the U.S. Food and Drug Administration.
Such delays can be fatal for people fighting for their lives. The Trump administration must beat back attacks on accelerated approval — and indeed, expand its use.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Insurers, bureaucrats shouldn’t deprive patients of lifesaving treatments
Sally C. Pipes
There are thousands of diseases without effective therapies of any kind. Accelerated approval represents the quickest way to get promising treatments to people desperate for them.
Imagine being told there’s a drug that might save your life — but your insurance won’t cover it for 18 months.
That’s the reality for patients under a new policy from Independence Blue Cross, a Philadelphia-based insurer. The insurer announced earlier this year that it will delay coverage of therapies that have received “accelerated approval” from the U.S. Food and Drug Administration.
Such delays can be fatal for people fighting for their lives. The Trump administration must beat back attacks on accelerated approval — and indeed, expand its use.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.